Hepion Pharmaceuticals, Inc. (HEPA)
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc. (HEPA) dilution facts from SEC filings
Snapshot as of Jun 30, 2026, built from 53 SEC filings.
- Shelf registration
- None on file in the filings reviewed
- At-the-market (ATM) program
- No active program in the filings reviewed
- Warrants outstanding
- 7 warrant series recorded as outstanding
Check another stock for dilution
Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.